M&A and equity raisings
6,065 deals since January 2025, with sources and adviser credits where available · as at 20 Nov 2026 · Venture rounds
US deals dated after 30 September 2026 are still being collected.
12 deals · US$1.8bndisclosed · Pharmaceutical Manufacturing · Clear
Columns
| Date | Target | Vendor | Acquirer | Type | Status | Value US$m | Sector | Advisers |
|---|---|---|---|---|---|---|---|---|
| Jun 2025 | Felix Pharmaceuticals Pvt | – | Advent International | Stake | Announced | – | Animal Health+2 | A&L Goodbody LLPLincoln International (sell-side)Guggenheim Securities (buy-side) |
| Sep 2025 | Zentiva | Advent International | GTCR | Acquisition | Announced | – | Pharma+1 | Goldman Sachs (sell-side)PJT Partners (sell-side)Freshfields (sell-side)Barclays (buy-side)BNP Paribas (buy-side)Morgan Stanley (buy-side)Kirkland & Ellis (buy-side) |
| 2026 | Istituto Biochimico Italiano Giovanni Lorenzini (IBI Lorenzini) | – | ACS Dobfar | Acquisition | Announced | – | Pharmaceutical Manufacturing+1 | Lincoln International (sell-side) |
| Jan 2026 | Nivagen Pharmaceuticals | – | PAI Pharma | Acquisition | Announced | – | Pharmaceutical Manufacturing+1 | Bourne Partners (buy-side)Kirkland & Ellis (buy-side)KPMG (buy-side) |
| Mar 2026 | Lonza Capsules & Health Ingredients division | Lonza Group AG | Lone Star Funds | Asset sale | Announced | – | Pharmaceutical Manufacturing+2 | Kirkland & Ellis (buy-side) |
| Mar 2026 | Manufacturing facility in Phoenix, AZ | Bristol Myers Squibb | Rovi | Asset sale | Completed | – | Pharmaceutical Manufacturing+1 | William Blair |
| May 2026 | MacroGenics GMP manufacturing site and CDMO operations | MacroGenics | Bora Pharmaceuticals Co. | Asset sale | Completed | 122.5 | Pharmaceutical Manufacturing+1 | Moelis & Company (sell-side)Sidley Austin (sell-side)Covington & Burling (sell-side)Jones Day (buy-side) |
| May 2026 | AmbioPharm | – | CordenPharma | Acquisition | Announced | – | Pharma Services+2 | Kirkland & EllisBNP Paribas (sell-side)Latham & Watkins (buy-side) |
| Jul 2026 | InfoRLife SA | Sergio Dusci | BC Partners | Stake | Announced | – | Pharma Services+1 | Latham & Watkins (buy-side) |
| Jul 2026 | Lannett | – | Aurobindo | Acquisition | Completed | 250.0 | Pharma+1 | Raymond JamesSullivan & Cromwell (buy-side) |
| Jul 2026 | PolyPeptide Group AG | – | Samsung Biologics Co. | Acquisition | Announced | 1,454.0 | Pharma Services+2 | J.P. Morgan (buy-side)EY (buy-side)O'Melveny & Myers (buy-side)Schellenberg Wittmer (buy-side) |
| Sep 2026 | portfolio of 20 mature medicines and three manufacturing sites | Sanofi | Cheplapharm | Asset sale | Announced | – | Pharma+1 | Freshfields (sell-side)Latham & Watkins (buy-side) |
Deals come from stock exchange announcements and filings, takeover and scheme documents, prospectuses, the advisers' own deal announcements and the press. How the data is built All countries counts every deal, wherever it is, including deals whose geography is not known.Country pages cover Australia, New Zealand and the United States. The United Kingdom, Canada, Singapore, China and India are planned.